Form 4: Oramed Pharmaceuticals: Chief Scientific Officer Miriam Kidron Reports Acquisition of Common Stock Through PSU Settlement

Miriam Kidron, Chief Scientific Officer of Oramed Pharmaceuticals, reports the acquisition of common stock through the settlement of performance stock units (PSUs).

Summary

• On February 11, 2025, Miriam Kidron, the Chief Scientific Officer of Oramed Pharmaceuticals, reported the acquisition of common stock.
• These shares were obtained through the settlement of performance stock units (PSUs) that vested on the same date.
• The PSUs were previously granted on January 4, 2024 (74,000 shares), January 2, 2025 (52,000 shares), and February 3, 2025 (66,667 shares).
• The total number of shares acquired is 192,667.
• Following these transactions, Kidron's total direct holdings in Oramed Pharmaceuticals common stock increased to 1,193,333 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects a routine transaction related to executive compensation. The vesting of PSUs suggests performance targets were met, which is mildly positive.

Positives

• The vesting of PSUs indicates that performance criteria were met, which could be viewed positively.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The acquisition of shares by a key executive could signal confidence in the company's future performance to shareholders.

Key Dates